STAT

Watchdog group calls for NIH to halt ‘dangerous’ study of sepsis treatment

A medical watchdog group contends patients in an NIH-funded trial are “unwitting guinea pigs in a physiology experiment that will not advance medical care for sepsis.”

A medical watchdog group is calling on the National Institutes of Health to immediately stop the enrollment of patients in a clinical trial of sepsis treatment and launch an investigation of how the study received approval, arguing that it puts patients at risk of serious harm, including death.

The group, Public Citizen, says in a letter dated Tuesday that the study’s protocol is also so “fundamentally flawed” that it will not produce reliable findings.

The problems with the “CLOVERS” study are so serious that “it is difficult to imagine any reasonable person agreeing to enroll … if he or she were fully informed of [its] true nature and risks,” wrote Dr. Sidney Wolfe and Dr. Michael Carome

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks